APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

OX40 Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global OX40 Receptor Agonist Industry Growth and Trends Forecast to 2032

2 January 2026105 pages

Choose your research edition.

Industry ResearchOX40 Receptor Agonist Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal OX40 Receptor Agonist Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal OX40 Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OX40 Receptor Agonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal OX40 Receptor Agonist Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global OX40 Receptor Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of OX40 Receptor Agonist include Roche, Pfizer, GlaxoSmithKline, Sorrento Therapeutics, Merk, Incyte, Glenmark, Bristol Myers Squibb and Bioinvent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global OX40 Receptor Agonist market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The OX40 Receptor Agonist market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global OX40 Receptor Agonist market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to OX40 Receptor Agonist.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global OX40 Receptor Agonist market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

OX40 Receptor Agonist Market by Company

Roche

Pfizer

GlaxoSmithKline

Sorrento Therapeutics

Merk

Incyte

Glenmark

Bristol Myers Squibb

Bioinvent

AstraZeneca (MedImmune)

Agenus

OX40 Receptor Agonist Segment by Type

Fully Human IgG1 Agonist mAb

Fully Human IgG2 Agonist Ab

Humanised IgG1 Agonist mAb

OX40 Receptor Agonist Segment by Application

Myasthenia Gravis

Psoriasis

Cancers

OX40 Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OX40 Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OX40 Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OX40 Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of OX40 Receptor Agonist manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of OX40 Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Fully Human IgG1 Agonist mAb Table 2. Major Company of Fully Human IgG2 Agonist Ab Table 3. Major Company of Humanised IgG1 Agonist mAb Table 4. Global OX40 Receptor Agonist Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 6. Global OX40 Receptor Agonist Sales Market Share in Volume by Type (2021-2026) Table 7. Global OX40 Receptor Agonist Sales by Type (2021-2026) & (US$ Million) Table 8. Global OX40 Receptor Agonist Sales Market Share in Value by Type (2021-2026) Table 9. Global OX40 Receptor Agonist Price by Type (2021-2026) & (US$/Unit) Table 10. Global OX40 Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 11. Global OX40 Receptor Agonist Sales Market Share in Volume by Type (2027-2032) Table 12. Global OX40 Receptor Agonist Sales by Type (2027-2032) & (US$ Million) Table 13. Global OX40 Receptor Agonist Sales Market Share in Value by Type (2027-2032) Table 14. Global OX40 Receptor Agonist Price by Type (2027-2032) & (US$/Unit) Table 15. North America OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 16. North America OX40 Receptor Agonist Sales by Type (2021-2026) & (US$ Million) Table 17. Europe OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 18. Europe OX40 Receptor Agonist Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific OX40 Receptor Agonist Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 22. Latin America OX40 Receptor Agonist Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa OX40 Receptor Agonist Sales by Type (2021-2026) & (US$ Million) Table 25. OX40 Receptor Agonist Industry Trends Table 26. OX40 Receptor Agonist Industry Drivers Table 27. OX40 Receptor Agonist Industry Opportunities and Challenges Table 28. OX40 Receptor Agonist Industry Restraints Table 29. Global OX40 Receptor Agonist Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global OX40 Receptor Agonist Revenue Market Share by Company (2021-2026) Table 31. Global OX40 Receptor Agonist Sales by Company (2021-2026) & (K Units) Table 32. Global OX40 Receptor Agonist Sales Share by Company (2021-2026) Table 33. Global OX40 Receptor Agonist Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global OX40 Receptor Agonist Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global OX40 Receptor Agonist Major Company Production Sites and Headquarters Table 36. Global OX40 Receptor Agonist Company, Product Type & Application Table 37. Global OX40 Receptor Agonist Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global OX40 Receptor Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global OX40 Receptor Agonist Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global OX40 Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 42. Global OX40 Receptor Agonist Sales Market Share in Volume by Region (2021-2026) Table 43. Global OX40 Receptor Agonist Sales by Region (2021-2026) & (US$ Million) Table 44. Global OX40 Receptor Agonist Sales Market Share in Value by Region (2021-2026) Table 45. Global OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global OX40 Receptor Agonist Sales by Region (2027-2032) & (K Units) Table 47. Global OX40 Receptor Agonist Sales Market Share in Volume by Region (2027-2032) Table 48. Global OX40 Receptor Agonist Sales by Region (2027-2032) & (US$ Million) Table 49. Global OX40 Receptor Agonist Sales Market Share in Value by Region (2027-2032) Table 50. Global OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global OX40 Receptor Agonist Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 53. Global OX40 Receptor Agonist Sales Market Share in Volume by Application (2021-2026) Table 54. Global OX40 Receptor Agonist Sales by Application (2021-2026) & (US$ Million) Table 55. Global OX40 Receptor Agonist Sales Market Share in Value by Application (2021-2026) Table 56. Global OX40 Receptor Agonist Price by Application (2021-2026) & (US$/Unit) Table 57. Global OX40 Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 58. Global OX40 Receptor Agonist Sales Market Share in Volume by Application (2027-2032) Table 59. Global OX40 Receptor Agonist Sales by Application (2027-2032) & (US$ Million) Table 60. Global OX40 Receptor Agonist Sales Market Share in Value by Application (2027-2032) Table 61. Global OX40 Receptor Agonist Price by Application (2027-2032) & (US$/Unit) Table 62. North America OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 63. North America OX40 Receptor Agonist Sales by Application (2021-2026) & (US$ Million) Table 64. Europe OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 65. Europe OX40 Receptor Agonist Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific OX40 Receptor Agonist Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 69. Latin America OX40 Receptor Agonist Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa OX40 Receptor Agonist Sales by Application (2021-2026) & (US$ Million) Table 72. Roche Company Information Table 73. Roche Business Overview Table 74. Roche OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Roche OX40 Receptor Agonist Product Portfolio Table 76. Roche Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Pfizer OX40 Receptor Agonist Product Portfolio Table 81. Pfizer Recent Development Table 82. GlaxoSmithKline Company Information Table 83. GlaxoSmithKline Business Overview Table 84. GlaxoSmithKline OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. GlaxoSmithKline OX40 Receptor Agonist Product Portfolio Table 86. GlaxoSmithKline Recent Development Table 87. Sorrento Therapeutics Company Information Table 88. Sorrento Therapeutics Business Overview Table 89. Sorrento Therapeutics OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio Table 91. Sorrento Therapeutics Recent Development Table 92. Merk Company Information Table 93. Merk Business Overview Table 94. Merk OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Merk OX40 Receptor Agonist Product Portfolio Table 96. Merk Recent Development Table 97. Incyte Company Information Table 98. Incyte Business Overview Table 99. Incyte OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Incyte OX40 Receptor Agonist Product Portfolio Table 101. Incyte Recent Development Table 102. Glenmark Company Information Table 103. Glenmark Business Overview Table 104. Glenmark OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Glenmark OX40 Receptor Agonist Product Portfolio Table 106. Glenmark Recent Development Table 107. Bristol Myers Squibb Company Information Table 108. Bristol Myers Squibb Business Overview Table 109. Bristol Myers Squibb OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio Table 111. Bristol Myers Squibb Recent Development Table 112. Bioinvent Company Information Table 113. Bioinvent Business Overview Table 114. Bioinvent OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Bioinvent OX40 Receptor Agonist Product Portfolio Table 116. Bioinvent Recent Development Table 117. AstraZeneca (MedImmune) Company Information Table 118. AstraZeneca (MedImmune) Business Overview Table 119. AstraZeneca (MedImmune) OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio Table 121. AstraZeneca (MedImmune) Recent Development Table 122. Agenus Company Information Table 123. Agenus Business Overview Table 124. Agenus OX40 Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Agenus OX40 Receptor Agonist Product Portfolio Table 126. Agenus Recent Development Table 127. North America OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. North America OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 129. North America OX40 Receptor Agonist Sales Market Share by Country (2021-2026) Table 130. North America OX40 Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 131. North America OX40 Receptor Agonist Sales Market Share Forecast by Country (2027-2032) Table 132. North America OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America OX40 Receptor Agonist Market Size by Country (2021-2026) & (US$ Million) Table 134. North America OX40 Receptor Agonist Market Share by Country (2021-2026) Table 135. North America OX40 Receptor Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America OX40 Receptor Agonist Market Share Forecast by Country (2027-2032) Table 137. Europe OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Europe OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 139. Europe OX40 Receptor Agonist Sales Market Share by Country (2021-2026) Table 140. Europe OX40 Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 141. Europe OX40 Receptor Agonist Sales Market Share Forecast by Country (2027-2032) Table 142. Europe OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe OX40 Receptor Agonist Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe OX40 Receptor Agonist Market Share by Country (2021-2026) Table 145. Europe OX40 Receptor Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe OX40 Receptor Agonist Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 149. Asia-Pacific OX40 Receptor Agonist Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific OX40 Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 151. Asia-Pacific OX40 Receptor Agonist Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific OX40 Receptor Agonist Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific OX40 Receptor Agonist Market Share by Country (2021-2026) Table 155. Asia-Pacific OX40 Receptor Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific OX40 Receptor Agonist Market Share Forecast by Country (2027-2032) Table 157. Latin America OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Latin America OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 159. Latin America OX40 Receptor Agonist Sales Market Share by Country (2021-2026) Table 160. Latin America OX40 Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 161. Latin America OX40 Receptor Agonist Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America OX40 Receptor Agonist Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America OX40 Receptor Agonist Market Share by Country (2021-2026) Table 165. Latin America OX40 Receptor Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America OX40 Receptor Agonist Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa OX40 Receptor Agonist Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa OX40 Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 171. Middle East and Africa OX40 Receptor Agonist Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa OX40 Receptor Agonist Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa OX40 Receptor Agonist Market Share by Country (2021-2026) Table 175. Middle East and Africa OX40 Receptor Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa OX40 Receptor Agonist Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. OX40 Receptor Agonist Distributors List Table 180. OX40 Receptor Agonist Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. OX40 Receptor Agonist Image Figure 2. Global OX40 Receptor Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OX40 Receptor Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global OX40 Receptor Agonist Sales (2021-2032) & (K Units) Figure 5. Fully Human IgG1 Agonist mAb Image Figure 6. Global Fully Human IgG1 Agonist mAb Sales YoY Growth (2021-2032) & (K Units) Figure 7. Fully Human IgG2 Agonist Ab Image Figure 8. Global Fully Human IgG2 Agonist Ab Sales YoY Growth (2021-2032) & (K Units) Figure 9. Humanised IgG1 Agonist mAb Image Figure 10. Global Humanised IgG1 Agonist mAb Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global OX40 Receptor Agonist Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global OX40 Receptor Agonist Market Share by Type 2025 VS 2032 Figure 13. North America OX40 Receptor Agonist Sales Market Share in Volume by Type in 2025 Figure 14. North America OX40 Receptor Agonist Sales Market Share in Value by Type in 2025 Figure 15. Europe OX40 Receptor Agonist Sales Market Share in Volume by Type in 2025 Figure 16. Europe OX40 Receptor Agonist Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific OX40 Receptor Agonist Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific OX40 Receptor Agonist Sales Market Share in Value by Type in 2025 Figure 19. Latin America OX40 Receptor Agonist Sales Market Share in Volume by Type in 2025 Figure 20. Latin America OX40 Receptor Agonist Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa OX40 Receptor Agonist Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa OX40 Receptor Agonist Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 OX40 Receptor Agonist Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Myasthenia Gravis Image Figure 26. Global Myasthenia Gravis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Psoriasis Image Figure 28. Global Psoriasis Sales YoY Growth (2021-2032) & (K Units) Figure 29. Cancers Image Figure 30. Global Cancers Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global OX40 Receptor Agonist Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global OX40 Receptor Agonist Market Share by Application 2025 VS 2032 Figure 33. North America OX40 Receptor Agonist Sales Market Share in Volume by Application in 2025 Figure 34. North America OX40 Receptor Agonist Sales Market Share in Value by Application in 2025 Figure 35. Europe OX40 Receptor Agonist Sales Market Share in Volume by Application in 2025 Figure 36. Europe OX40 Receptor Agonist Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific OX40 Receptor Agonist Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific OX40 Receptor Agonist Sales Market Share in Value by Application in 2025 Figure 39. Latin America OX40 Receptor Agonist Sales Market Share in Volume by Application in 2025 Figure 40. Latin America OX40 Receptor Agonist Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa OX40 Receptor Agonist Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa OX40 Receptor Agonist Sales Market Share in Value by Application in 2025 Figure 43. North America OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America OX40 Receptor Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America OX40 Receptor Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe OX40 Receptor Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe OX40 Receptor Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific OX40 Receptor Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific OX40 Receptor Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America OX40 Receptor Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America OX40 Receptor Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa OX40 Receptor Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa OX40 Receptor Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. OX40 Receptor Agonist Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. OX40 Receptor Agonist Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Fully Human IgG1 Agonist mAb
  • Fully Human IgG2 Agonist Ab
  • Humanised IgG1 Agonist mAb
Applications
  • Myasthenia Gravis
  • Psoriasis
  • Cancers
Companies covered
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Sorrento Therapeutics
  • Merk
  • Incyte
  • Glenmark
  • Bristol Myers Squibb
  • Bioinvent
  • AstraZeneca (MedImmune)
  • Agenus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global OX40 Receptor Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global OX40 Receptor Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.3 OX40 Receptor Agonist Market by Type
  6. 1.3.1 Fully Human IgG1 Agonist mAb
  7. 1.3.2 Fully Human IgG2 Agonist Ab
  8. 1.3.3 Humanised IgG1 Agonist mAb
  9. 1.4 Global OX40 Receptor Agonist Market Size by Type
  10. 1.4.1 Global OX40 Receptor Agonist Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global OX40 Receptor Agonist Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global OX40 Receptor Agonist Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America OX40 Receptor Agonist Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe OX40 Receptor Agonist Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific OX40 Receptor Agonist Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America OX40 Receptor Agonist Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa OX40 Receptor Agonist Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 OX40 Receptor Agonist Industry Trends
  2. 2.2 OX40 Receptor Agonist Industry Drivers
  3. 2.3 OX40 Receptor Agonist Industry Opportunities and Challenges
  4. 2.4 OX40 Receptor Agonist Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by OX40 Receptor Agonist Revenue (2021-2026)
  2. 3.2 Global Top Players by OX40 Receptor Agonist Sales (2021-2026)
  3. 3.3 Global Top Players by OX40 Receptor Agonist Price (2021-2026)
  4. 3.4 Global OX40 Receptor Agonist Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global OX40 Receptor Agonist Major Company Production Sites & Headquarters
  6. 3.6 Global OX40 Receptor Agonist Company, Product Type & Application
  7. 3.7 Global OX40 Receptor Agonist Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global OX40 Receptor Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 OX40 Receptor Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 OX40 Receptor Agonist Tier 1, Tier 2, and Tier 3
4 OX40 Receptor Agonist Regional Status and Outlook
  1. 4.1 Global OX40 Receptor Agonist Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global OX40 Receptor Agonist Historic Market Size by Region
  3. 4.2.1 Global OX40 Receptor Agonist Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global OX40 Receptor Agonist Sales in Value by Region (2021-2026)
  5. 4.2.3 Global OX40 Receptor Agonist Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global OX40 Receptor Agonist Forecasted Market Size by Region
  7. 4.3.1 Global OX40 Receptor Agonist Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global OX40 Receptor Agonist Sales in Value by Region (2027-2032)
  9. 4.3.3 Global OX40 Receptor Agonist Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 OX40 Receptor Agonist by Application
  1. 5.1 OX40 Receptor Agonist Market by Application
  2. 5.1.1 Myasthenia Gravis
  3. 5.1.2 Psoriasis
  4. 5.1.3 Cancers
  5. 5.2 Global OX40 Receptor Agonist Market Size by Application
  6. 5.2.1 Global OX40 Receptor Agonist Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global OX40 Receptor Agonist Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global OX40 Receptor Agonist Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America OX40 Receptor Agonist Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe OX40 Receptor Agonist Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific OX40 Receptor Agonist Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America OX40 Receptor Agonist Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa OX40 Receptor Agonist Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Roche
  2. 6.1.1 Roche Company Information
  3. 6.1.2 Roche Business Overview
  4. 6.1.3 Roche OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Roche OX40 Receptor Agonist Product Portfolio
  6. 6.1.5 Roche Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer OX40 Receptor Agonist Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 GlaxoSmithKline
  14. 6.3.1 GlaxoSmithKline Company Information
  15. 6.3.2 GlaxoSmithKline Business Overview
  16. 6.3.3 GlaxoSmithKline OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline OX40 Receptor Agonist Product Portfolio
  18. 6.3.5 GlaxoSmithKline Recent Developments
  19. 6.4 Sorrento Therapeutics
  20. 6.4.1 Sorrento Therapeutics Company Information
  21. 6.4.2 Sorrento Therapeutics Business Overview
  22. 6.4.3 Sorrento Therapeutics OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio
  24. 6.4.5 Sorrento Therapeutics Recent Developments
  25. 6.5 Merk
  26. 6.5.1 Merk Company Information
  27. 6.5.2 Merk Business Overview
  28. 6.5.3 Merk OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merk OX40 Receptor Agonist Product Portfolio
  30. 6.5.5 Merk Recent Developments
  31. 6.6 Incyte
  32. 6.6.1 Incyte Company Information
  33. 6.6.2 Incyte Business Overview
  34. 6.6.3 Incyte OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Incyte OX40 Receptor Agonist Product Portfolio
  36. 6.6.5 Incyte Recent Developments
  37. 6.7 Glenmark
  38. 6.7.1 Glenmark Company Information
  39. 6.7.2 Glenmark Business Overview
  40. 6.7.3 Glenmark OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Glenmark OX40 Receptor Agonist Product Portfolio
  42. 6.7.5 Glenmark Recent Developments
  43. 6.8 Bristol Myers Squibb
  44. 6.8.1 Bristol Myers Squibb Company Information
  45. 6.8.2 Bristol Myers Squibb Business Overview
  46. 6.8.3 Bristol Myers Squibb OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio
  48. 6.8.5 Bristol Myers Squibb Recent Developments
  49. 6.9 Bioinvent
  50. 6.9.1 Bioinvent Company Information
  51. 6.9.2 Bioinvent Business Overview
  52. 6.9.3 Bioinvent OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Bioinvent OX40 Receptor Agonist Product Portfolio
  54. 6.9.5 Bioinvent Recent Developments
  55. 6.10 AstraZeneca (MedImmune)
  56. 6.10.1 AstraZeneca (MedImmune) Company Information
  57. 6.10.2 AstraZeneca (MedImmune) Business Overview
  58. 6.10.3 AstraZeneca (MedImmune) OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio
  60. 6.10.5 AstraZeneca (MedImmune) Recent Developments
  61. 6.11 Agenus
  62. 6.11.1 Agenus Company Information
  63. 6.11.2 Agenus Business Overview
  64. 6.11.3 Agenus OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Agenus OX40 Receptor Agonist Product Portfolio
  66. 6.11.5 Agenus Recent Developments
7 North America by Country
  1. 7.1 North America OX40 Receptor Agonist Sales by Country
  2. 7.1.1 North America OX40 Receptor Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America OX40 Receptor Agonist Sales by Country (2021-2026)
  4. 7.1.3 North America OX40 Receptor Agonist Sales Forecast by Country (2027-2032)
  5. 7.2 North America OX40 Receptor Agonist Market Size by Country
  6. 7.2.1 North America OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America OX40 Receptor Agonist Market Size by Country (2021-2026)
  8. 7.2.3 North America OX40 Receptor Agonist Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe OX40 Receptor Agonist Sales by Country
  2. 8.1.1 Europe OX40 Receptor Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe OX40 Receptor Agonist Sales by Country (2021-2026)
  4. 8.1.3 Europe OX40 Receptor Agonist Sales Forecast by Country (2027-2032)
  5. 8.2 Europe OX40 Receptor Agonist Market Size by Country
  6. 8.2.1 Europe OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe OX40 Receptor Agonist Market Size by Country (2021-2026)
  8. 8.2.3 Europe OX40 Receptor Agonist Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific OX40 Receptor Agonist Sales by Country
  2. 9.1.1 Asia-Pacific OX40 Receptor Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific OX40 Receptor Agonist Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific OX40 Receptor Agonist Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific OX40 Receptor Agonist Market Size by Country
  6. 9.2.1 Asia-Pacific OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific OX40 Receptor Agonist Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific OX40 Receptor Agonist Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America OX40 Receptor Agonist Sales by Country
  2. 10.1.1 South America OX40 Receptor Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America OX40 Receptor Agonist Sales by Country (2021-2026)
  4. 10.1.3 South America OX40 Receptor Agonist Sales Forecast by Country (2027-2032)
  5. 10.2 South America OX40 Receptor Agonist Market Size by Country
  6. 10.2.1 South America OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America OX40 Receptor Agonist Market Size by Country (2021-2026)
  8. 10.2.3 South America OX40 Receptor Agonist Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa OX40 Receptor Agonist Sales by Country
  2. 11.1.1 Middle East and Africa OX40 Receptor Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa OX40 Receptor Agonist Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa OX40 Receptor Agonist Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa OX40 Receptor Agonist Market Size by Country
  6. 11.2.1 Middle East and Africa OX40 Receptor Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa OX40 Receptor Agonist Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa OX40 Receptor Agonist Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 OX40 Receptor Agonist Value Chain Analysis
  2. 12.1.1 OX40 Receptor Agonist Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 OX40 Receptor Agonist Production Mode & Process
  7. 12.2 OX40 Receptor Agonist Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 OX40 Receptor Agonist Distributors
  10. 12.2.3 OX40 Receptor Agonist Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst